An FDA-approved, pharmaceutical-grade formulation of CBD could inhibit infections by SARS-CoV-2, after a study showed promise in human lung cells and in mice, UChicago Medicine says.
Cannabidiol, or CBD, a product of the cannabis plant, showed a significant negative association with SARS-CoV-2 positive tests in a national sample of medical records of patients taking the drug for treating epilepsy, UChicago Medicine said in a statement. The study was published yesterday in Science Advances.
Researchers say clinical trials should be done to see whether the already FDA-approved drug should be used to prevent, or as an early treatment for, COVID-19.
If there are infection-fighting effects, they can't be gotten from recreational use of pot. Researchers emphasize that "COVID-blocking effects of CBD were confined strictly to high purity, high concentrations of CBD."
Download Modern Healthcare’s app to stay informed when industry news breaks.
"Closely related cannabinoids such as CBDA, CBDV and THC, the psychoactive element enriched in marijuana plants, did not have the same power," the statement said. "In fact, combining CBD with equal amounts of THC actually reduced the efficacy of CBD."
At first, researchers looked at CBD to calm the dramatic and damaging symptoms of COVID.
“CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm.’ Surprisingly, it directly inhibited viral replication in lung cells,” said Marsha Rosner, a senior author of the study.
What they found was, although CBD did not affect the ability of SARS-CoV-2 to enter the cell, it was was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.
The study was supported by a BIG Vision grant from the University of Chicago, the National Institutes of Health and the Leona M. & Harris B. Helmsley Charitable Trust.
This story first appeared in our sister publication, Crain's Chicago Business.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
